REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
4. Caparica R, Mak MP, Rocha CH, et al. Pulmonary nodules in patients with nonpulmonary cancer: not always metastases. J Glob Oncol 2016;2:138-44.
5. Chen H, Stoltzfus KC, Lehrer EJ, et al. The epidemiology of lung metastases. Front Med 2021;8:723396.
6. Ha D, Choi H, Chevalier C, Zell K, Wang XF, Mazzone PJ. Survival in patients with metachronous second primary lung cancer. Ann Am Thorac Soc 2015;12:79-84.
7. Jamil A. and Kasi A. Lung metastasis. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553111/ [Last accessed on 27 Mar 2024].
8. Wang R, Yin Z, Liu L, et al. Second primary lung cancer after breast cancer: a population-based study of 6,269 women. Front Oncol 2018;8:427.
9. Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci 2019;20:2272.
10. Mangiameli G, Cioffi U, Alloisio M, Testori A. Lung metastases: current surgical indications and new perspectives. Front Surg 2022;9:884915.
11. Antonoff MB, Sofocleous CT, Callstrom MR, Nguyen QN. The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases. J Thorac Cardiovasc Surg 2022;163:495-502.
12. Dama E, Colangelo T, Fina E, et al. Biomarkers and lung cancer early detection: state of the art. Cancers 2021;13:3919.
13. Haranguș A, Berindan-Neagoe I, Todea DA, Șimon I, Șimon M. Noncoding RNAs and liquid biopsy in lung cancer: a literature review. Diagnostics 2019;9:216.
14. de Fraipont F, Gazzeri S, Cho WC, Eymin B. Circular RNAs and RNA splice variants as biomarkers for prognosis and therapeutic response in the liquid biopsies of lung cancer patients. Front Genet 2019;10:390.
15. Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. a systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res 2021;230:164-96.
16. Patel U, Susman D, Allan AL. Influence of extracellular vesicles on lung stromal cells during breast cancer metastasis. Int J Mol Sci 2023;24:11801.
17. Hinestrosa JP, Kurzrock R, Lewis JM, et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med 2022;2:29.
18. Liu Z, Kong Y, Dang Q, et al. Liquid biopsy in pre-metastatic niche: from molecular mechanism to clinical application. Front Immunol 2022;13:958360.
19. Habli Z, AlChamaa W, Saab R, Kadara H, Khraiche ML. Circulating tumor cell detection technologies and clinical utility: challenges and opportunities. Cancers 2020;12:1930.
20. Agashe R, Kurzrock R. Circulating tumor cells: from the laboratory to the cancer clinic. Cancers 2020;12:2361.
21. Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010;16:398-406.
22. Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8.
23. Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol 2019;14:343-57.
24. Yendamuri S, Vaporciyan AA, Zaidi T, et al. 3p and 10q deletions detected by fluorescence in situ hybridization (FISH): A potential new tool for early detection of non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:7606.
25. Chen CC, Bai CH, Lee KY, Chou YT, Pan ST, Wang YH. Evaluation of the diagnostic accuracy of bronchial brushing cytology in lung cancer: A meta-analysis. Cancer Cytopathol 2021;129:739-49.
26. Pavel AB, Campbell JD, Liu G, et al. AEGIS Study Team. Alterations in bronchial airway miRNA expression for lung cancer detection. Cancer Prev Res 2017;10:651-9.
27. Matthiesen R. MS-based biomarker discovery in bronchoalveolar lavage fluid for lung cancer. Proteomics Clin Appl 2020;14:e1900077.
28. Engel E, Schmidt B, Carstensen T, et al. Detection of tumor-specific mRNA in cell-free bronchial lavage supernatant in patients with lung cancer. Ann N Y Acad Sci 2004;1022:140-6.
29. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008;7:81.
30. Schmidt B, Rehbein G, Fleischhacker M. Liquid profiling in lung cancer - quantification of extracellular mirnas in bronchial lavage. In: Gahan PB, Fleischhacker M, Schmidt B, editors. Circulating Nucleic Acids in Serum and Plasma - CNAPS IX. Cham: Springer International Publishing; 2016. pp. 33-7.
31. Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med 2001;164:731-7.
32. Keogh RJ, Riches JC. The use of breath analysis in the management of lung cancer: is it ready for primetime? Curr Oncol 2022;29:7355-78.
33. Wang P, Huang Q, Meng S, et al. Identification of lung cancer breath biomarkers based on perioperative breathomics testing: a prospective observational study. EClinicalMedicine 2022;47:101384.
34. van der Schee M, Pinheiro H, Gaude E, et al. Breath biopsy for early detection and precision medicine in cancer. Ecancermedicalscience 2018;12:ed84.
35. Marzorati D, Mainardi L, Sedda G, Gasparri R, Spaggiari L, Cerveri P. A review of exhaled breath: a key role in lung cancer diagnosis. J Breath Res 2019;13:034001.
36. Jia Z, Patra A, Kutty VK, Venkatesan T. Critical review of volatile organic compound analysis in breath and in vitro cell culture for detection of lung cancer. Metabolites 2019;9:52.
37. Kubáň P, Foret F. Exhaled breath condensate: determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. A review. Anal Chim Acta 2013;805:1-18.
38. Rahimpour E, Khoubnasabjafari M, Jouyban-Gharamaleki V, Jouyban A. Non-volatile compounds in exhaled breath condensate: review of methodological aspects. Anal Bioanal Chem 2018;410:6411-40.
39. Campanella A, De Summa S, Tommasi S. Exhaled breath condensate biomarkers for lung cancer. J Breath Res 2019;13:044002.
40. Effros RM, Peterson B, Casaburi R, et al. Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects. J Appl Physiol 2005;99:1286-92.
41. Horváth I, Hunt J, Barnes PJ, et al. ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523-48.
43. Shi M, Han W, Loudig O, et al. Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination. Sci Rep 2023;13:6620.
44. Pinkerton M, Chinchilli V, Banta E, et al. Differential expression of microRNAs in exhaled breath condensates of patients with asthma, patients with chronic obstructive pulmonary disease, and healthy adults. J Allergy Clin Immunol 2013;132:217-9.
45. Pérez-Sánchez C, Barbarroja N, Pantaleão LC, et al. Clinical utility of microRNAs in exhaled breath condensate as biomarkers for lung cancer. J Pers Med 2021;11:111.
46. Mendes FC, Paciência I, Ferreira AC, et al. Development and validation of exhaled breath condensate microRNAs to identify and endotype asthma in children. PLoS One 2019;14:e0224983.
47. Faversani A, Favero C, Dioni L, et al. An EBC/Plasma miRNA signature discriminates lung adenocarcinomas from pleural mesothelioma and healthy controls. Front Oncol 2021;11:643280.
48. Lucchetti D, Santini G, Perelli L, et al. Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients. Eur Respir J 2021;58:2003024.
49. Dobhal G, Datta A, Ayupova D, Teesdale-Spittle P, Goreham RV. Isolation, characterisation and detection of breath-derived extracellular vesicles. Sci Rep 2020;10:17381.
50. Sinha A, Yadav AK, Chakraborty S, et al. Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases. J Allergy Clin Immunol 2013;132:219-22.
51. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 2018;9:402.
52. Ketting RF. microRNA Biogenesis and Function. In: Großhans H, editor. Regulation of microRNAs. New York: Springer US; 2010. pp. 1-14.
53. Ardekani AM, Naeini MM. The role of MicroRNAs in human diseases. Avicenna J Med Biotechnol 2010;2:161-79.
54. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer--a brief overview. Adv Biol Regul 2015;57:1-9.
55. Santos RM, Moreno C, Zhang WC. Non-coding RNAs in lung tumor initiation and progression. Int J Mol Sci 2020;21:2774.
56. Rohan TE, Wang T, Weinmann S, et al. A miRNA expression signature in breast tumor tissue is associated with risk of distant metastasis. Cancer Res 2019;79:1705-13.
57. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
58. Zhu X, Kudo M, Huang X, et al. Frontiers of MicroRNA signature in non-small cell lung cancer. Front Cell Dev Biol 2021;9:643942.
59. Chakrabortty A, Patton DJ, Smith BF, Agarwal P. miRNAs: Potential as biomarkers and therapeutic targets for cancer. Genes 2023;14:1375.
60. Ware AP, Kabekkodu SP, Chawla A, Paul B, Satyamoorthy K. Diagnostic and prognostic potential clustered miRNAs in bladder cancer. 3 Biotech 2022;12:173.
61. Mao S, Lu Z, Zheng S, et al. Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer. J Exp Clin Cancer Res 2020;39:193.
62. Quirico L, Orso F. The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies. Cancer Drug Resist 2020;3:117-39.
63. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002;2:569-79.
64. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J Clin Invest 2016;126:1139-43.
65. Mitchell MI, Loudig O. Communicator extraordinaire: extracellular vesicles in the tumor microenvironment are essential local and long-distance mediators of cancer metastasis. Biomedicines 2023;11:2534.
66. Brena D, Huang MB, Bond V. Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis. Transl Oncol 2022;15:101286.
67. Ozawa PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, de Souza Fonseca Ribeiro EM, Cavalli LR. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 2018;172:713-23.
68. He S, Li Z, Yu Y, et al. Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. Exp Cell Res 2019;379:203-13.
69. Yang M, Xiao R, Wang X, et al. MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer. Ann Transl Med 2022;10:203.
70. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012;109:E2110-6.
71. Wong GL, Abu Jalboush S, Lo HW. Exosomal MicroRNAs and organotropism in breast cancer metastasis. Cancers 2020;12:1827.
72. Zeng Z, Li Y, Pan Y, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun 2018;9:5395.
73. Zhong Y, Ding X, Bian Y, et al. Discovery and validation of extracellular vesicle-associated miRNAs as noninvasive detection biomarkers for early-stage non-small-cell lung cancer. Mol Oncol 2021;15:2439-52.
74. Gao S, Guo W, Liu T, et al. Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Sci 2022;113:648-59.
75. Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: communication from a distance. Dev Cell 2019;49:347-60.
76. Mitchell MI, Ma J, Carter CL, Loudig O. Circulating exosome cargoes contain functionally diverse cancer biomarkers: from biogenesis and function to purification and potential translational utility. Cancers 2022;14:3350.
77. Couch Y, Buzàs EI, Di Vizio D, et al. A brief history of nearly EV-erything - The rise and rise of extracellular vesicles. J Extracell Vesicles 2021;10:e12144.
78. Logozzi M, Angelini DF, Giuliani A, et al. Increased plasmatic levels of PSA-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia: a prospective study. Cancers 2019;11:1449.
79. Newman LA, Useckaite Z, Johnson J, Sorich MJ, Hopkins AM, Rowland A. Selective isolation of liver-derived extracellular vesicles redefines performance of miRNA biomarkers for non-alcoholic fatty liver disease. Biomedicines 2022;10:195.
80. Chiasserini D, van Weering JR, Piersma SR, et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J Proteomics 2014;106:191-204.
81. Choudhary I, Vo T, Paudel K, et al. Vesicular and extravesicular protein analyses from the airspaces of ozone-exposed mice revealed signatures associated with mucoinflammatory lung disease. Sci Rep 2021;11:23203.
82. Mimmi S, Zimbo AM, Rotundo S, et al. SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infections. Clin Chem Lab Med 2023;61:1518-24.
83. Miranda J, Paules C, Nair S, et al. Placental exosomes profile in maternal and fetal circulation in intrauterine growth restriction - Liquid biopsies to monitoring fetal growth. Placenta 2018;64:34-43.
84. Than UTT, Guanzon D, Broadbent JA, Parker TJ, Leavesley DI. Deep sequencing micrornas from extracellular membrane vesicles revealed the association of the vesicle cargo with cellular origin. Int J Mol Sci 2020;21:1141.
85. Yu H, Guan Z, Cuk K, Brenner H, Zhang Y. Circulating microRNA biomarkers for lung cancer detection in Western populations. Cancer Med 2018;7:4849-62.
86. Asakura K, Kadota T, Matsuzaki J, et al. A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. Commun Biol 2020;3:134.
87. Vykoukal J, Fahrmann JF, Patel N, et al. Contributions of circulating microRNAs for early detection of lung cancer. Cancers 2022;14:4221.
88. Wang X, Tian L, Lu J, Ng IO. Exosomes and cancer - diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis 2022;11:54.
89. He X, Park S, Chen Y, Lee H. Extracellular vesicle-associated miRNAs as a biomarker for lung cancer in liquid biopsy. Front Mol Biosci 2021;8:630718.
90. Zhang C, Yang J, Chen Y, et al. miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer. Gastric Cancer 2022;25:360-74.
91. Geng N, Qi Y, Qin W, et al. Two microRNAs of plasma-derived small extracellular vesicles as biomarkers for metastatic non-small cell lung cancer. BMC Pulm Med 2023;23:259.
92. Tanaka R, Yoshinouchi S, Karouji K, et al. A mouse model of lung cancer induced via intranasal injection for anticancer drug screening and evaluation of pathology. FEBS Open Bio 2023;13:51-9.
93. Kang Y, Omura M, Suzuki A, et al. Proliferation of human lung cancer in an orthotopic transplantation mouse model. Exp Ther Med 2010;1:471-5.
94. Madero-Visbal RA, Colon JF, Hernandez IC, et al. Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer. Surg Oncol 2012;21:23-9.
95. Stevens LE, Arnal-Estapé A, Nguyen DX. Pre-conditioning the airways of mice with bleomycin increases the efficiency of orthotopic lung cancer cell engraftment. J Vis Exp 2018;136:56650.
96. Liu Y, Hou Y, Hua Y, Gao Y. A device to collect exhaled breath to study biomarkers in small animal models. Available from: https://www.biorxiv.org/content/10.1101/511931v1.full.pdf+html [Last accessed on 28 Mar 2024].
97. Mitchell MI, Ben-Dov IZ, Liu C, et al. Extracellular vesicle capture by AnTibody of CHoice and enzymatic release (EV-CATCHER): a customizable purification assay designed for small-RNA biomarker identification and evaluation of circulating small-EVs. J Extracell Vesicles 2021;10:e12110.
98. Loudig O, Liu C, Rohan T, Ben-Dov IZ. Retrospective MicroRNA sequencing: complementary DNA library preparation protocol using formalin-fixed paraffin-embedded RNA specimens. J Vis Exp 2018;135:57471.
99. Mensà E, Giuliani A, Matacchione G, et al. Circulating miR-146a in healthy aging and type 2 diabetes: age- and gender-specific trajectories. Mech Ageing Dev 2019;180:1-10.
100. Wu C, Zhou S, Mitchell MI, et al. Coupling suspension trapping-based sample preparation and data-independent acquisition mass spectrometry for sensitive exosomal proteomic analysis. Anal Bioanal Chem 2022;414:2585-95.
101. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
102. Agiostratidou G, Li M, Suyama K, et al. Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res 2009;69:5030-8.
103. Kim S, Yao J, Suyama K, et al. Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis. Cancer Res 2014;74:3695-706.
104. Fan J, Xu G, Chang Z, Zhu L, Yao J. miR-210 transferred by lung cancer cell-derived exosomes may act as proangiogenic factor in cancer-associated fibroblasts by modulating JAK2/STAT3 pathway. Clin Sci 2020;134:807-25.
105. Ding J, Xu Z, Zhang Y, et al. Exosome-mediated miR-222 transferring: an insight into NF-κB-mediated breast cancer metastasis. Exp Cell Res 2018;369:129-38.
106. Perez SM, Brinton LT, Kelly KA. Plectin in cancer: from biomarker to therapeutic target. Cells 2021;10:2246.
107. Fei F, Qu J, Zhang M, Li Y, Zhang S. S100A4 in cancer progression and metastasis: a systematic review. Oncotarget 2017;8:73219-39.
108. Zheng G, Leone JP. Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. J Oncol 2022;2022:1734049.
109. Serganova I, Moroz E, Vider J, et al. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J 2009;23:2662-72.
110. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005;7:R444-54.
111. Perry MR, Neal M, Hawks R, et al. A novel sulfur mustard (HD) vapor inhalation exposure model of pulmonary toxicity for the efficacy evaluation of candidate medical countermeasures. Inhal Toxicol 2021;33:221-33.
112. Neuhaus S, Seifert L, Vautz W, Nolte J, Bufe A, Peters M. Comparison of metabolites in exhaled breath and bronchoalveolar lavage fluid samples in a mouse model of asthma. J Appl Physiol 2011;111:1088-95.
113. Jonasson S, Magnusson R, Wingfors H, et al. Potential exhaled breath biomarkers identified in chlorine-exposed mice. J Anal Toxicol 2024;48:171-9.
114. Paris D, Palomba L, Mirra V, et al. NMR profiling of exhaled breath condensate defines different metabolic phenotypes of non-cystic fibrosis bronchiectasis. Int J Mol Sci 2020;21:8600.
115. Kulshreshtha A, Ahmad T, Agrawal A, Ghosh B. Proinflammatory role of epithelial cell-derived exosomes in allergic airway inflammation. J Allergy Clin Immunol 2013;131:1194-203, 1203.e1-14.
116. Lee H, Zhang D, Zhu Z, Dela Cruz CS, Jin Y. Epithelial cell-derived microvesicles activate macrophages and promote inflammation via microvesicle-containing microRNAs. Sci Rep 2016;6:35250.
117. Shikano S, Gon Y, Maruoka S, et al. Increased extracellular vesicle miRNA-466 family in the bronchoalveolar lavage fluid as a precipitating factor of ARDS. BMC Pulm Med 2019;19:110.
118. Stachowiak Z, Wojsyk-Banaszak I, Jończyk-Potoczna K, Narożna B, Langwiński W, Szczepankiewicz A. Extracellular vesicles-derived miRNAs as mediators of pulmonary exacerbation in pediatric cystic fibrosis. J Breath Res 2023;17:026005.
119. An J, McDowell A, Kim YK, Kim TB. Extracellular vesicle-derived microbiome obtained from exhaled breath condensate in patients with asthma. Ann Allergy Asthma Immunol 2021;126:729-31.
120. Bidola P, Martins de Souza E Silva J, Achterhold K, et al. A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography. Sci Rep 2019;9:1325.
121. Drosten M, Guerra C, Barbacid M. Genetically engineered mouse models of k-ras-driven lung and pancreatic tumors: validation of therapeutic targets. Cold Spring Harb Perspect Med 2018;8:a031542.
122. Fitzgerald B, Connolly KA, Cui C, et al. A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. Cell Rep Methods 2021;1:100080.
123. Foggetti G, Li C, Cai H, et al. Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo. Cancer Discov 2021;11:1736-53.
124. Politi K, Fan PD, Shen R, Zakowski M, Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 2010;3:111-9.
125. Ramelow J, Brooks CD, Gao L, et al. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer 2020;20:738.
126. Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med 2022;20:206.
127. Chiappetta M, Salvatore L, Congedo MT, et al. Management of single pulmonary metastases from colorectal cancer: state of the art. World J Gastrointest Oncol 2022;14:820-32.
128. Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biol Ther 2018;19:858-68.
129. Tyagi A, Sharma S, Wu K, et al. Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung. Nat Commun 2021;12:474.
130. Patel HD, Singla N, Ghandour RA, et al. Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. Cancer 2019;125:3947-52.
131. Zhang J, Kulkarni HR, Singh A, Baum RP. Complete regression of lung metastases in a patient with metastatic castration-resistant prostate cancer using 177Lu-PSMA radioligand therapy. Clin Nucl Med 2020;45:e48-50.
